The FDA’s Latest Peptide Actions: What They Could Mean for Functional Medicine
The FDA has taken another meaningful step in its ongoing review of peptide compounding, signaling a potential shift in how certain peptide substances may be evaluated for future use by 503A compounding pharmacies.
While the recent Pharmacy Compounding Advisory Committee (PCAC) meeting generated considerable excitement throughout the functional medicine community, it’s important to understand exactly what happened—and just as importantly—what hasn’t happened yet.
At MyPracticeConnect, we believe providers deserve more than headlines. They deserve context.
A Broader FDA Initiative
The July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting was not an isolated event—it was the first phase of a broader FDA initiative to evaluate multiple peptide substances for potential inclusion on the 503A Bulk Drug Substances List.
Earlier this year, the FDA removed 12 nominated peptides from Category 2 of the FDA’s Bulk Drug Substances Under Evaluation list, allowing them to move into the formal scientific review process.
The FDA announced that the nominated peptide substances would be reviewed in phases by the Pharmacy Compounding Advisory Committee rather than addressed in a single meeting.
What Happened at the July PCAC Meeting?
During the July 23–24, 2026 meeting, the advisory committee reviewed seven nominated peptides:
| BPC-157 | KPV |
| TB-500 | MOTS-c |
| Epitalon | Semax |
| Emideltide (DSIP) | |
Following scientific review and discussion, the committee recommended that six of the seven peptides be considered for inclusion on the FDA’s 503A Bulk Drug Substances List.
Emideltide (DSIP) did not receive a favorable recommendation.
The clinical descriptions above reflect areas of ongoing scientific investigation and are not FDA-approved indications.
What About the Remaining Five Peptides?
The FDA’s review process is continuing.
Five additional peptide substances were removed from Category 2 but were not included in the July meeting. The FDA has indicated they are expected to be reviewed during a future Pharmacy Compounding Advisory Committee meeting before February 2027.
This reinforces that the FDA’s current actions represent an ongoing review of multiple peptide substances—not a single isolated decision.
What Happens Next?
Although the advisory committee’s recommendations are encouraging, they do not change current regulations.
“The committee’s vote was advisory only and does not carry the force of law.”
Before any substance can become eligible for routine 503A compounding, several regulatory steps remain:
Only after completion of this process would routine 503A compounding become permissible under the new rule.
How Long Could the Process Take?
There is no official FDA timeline for completion of this rulemaking process.
As with all FDA rulemaking, timelines may change.
Why This Matters
For functional medicine providers, these developments represent meaningful progress.
Many of these peptide therapies have generated significant clinical interest, and the FDA’s willingness to formally evaluate them reflects a growing recognition that providers and patients are seeking additional therapeutic options.
At the same time, it is essential to distinguish scientific progress from regulatory approval.
The July advisory committee vote should be viewed as an important milestone—not the finish line.
The MPC Perspective
At MyPracticeConnect, we encourage providers to remain informed, practice responsibly, and continue making prescribing decisions based on current regulations—not anticipated outcomes.
As this regulatory process evolves, we will continue monitoring FDA actions and translating complex regulatory developments into practical guidance for functional medicine providers.
Regulatory changes rarely happen overnight. They move through advisory committees, public comment periods, and formal FDA rulemaking before becoming policy.
Our goal isn’t simply to report what’s happening—it’s to help you understand what it means for your practice, your patients, and the future of functional medicine.
Trusted Regulatory Resources
Bookmark these organizations to stay informed on FDA compounding regulations and related policy developments.
MyPracticeConnect helps providers translate complex FDA actions, compounding policy developments, and emerging regulatory changes into practical information for functional medicine practices.
|
|
Written By
Shelley Junkin
Chief Operating Officer, MyPracticeConnect®
Shelley supports provider education, clinical implementation, and practice growth initiatives designed to help medical professionals confidently integrate functional and emerging therapies into patient care.
|
This article is intended for educational purposes only and should not be construed as legal, medical, or regulatory advice. References to peptide substances, potential clinical applications, advisory committee recommendations, ongoing scientific investigation, or future 503A eligibility should not be interpreted as FDA approval, endorsement, or authorization for routine compounding or clinical use. Providers should consult official FDA guidance, applicable federal and state regulations, pharmacy counsel, and independent clinical judgment when making prescribing, compounding, operational, or patient-care decisions.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting. July 23–24, 2026.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- U.S. Food and Drug Administration. Federal Register Notice. April 2026.
- George Maiorano. FDA’s Recent Peptide Decisions: What the July 2026 PCAC Recommendations Mean for Providers and Patients. American Wellness Pharmacy.
- Regulatory Affairs Professionals Society (RAPS). FDA Considers Adding a Dozen Peptides to Its Bulk Drug Compounding List.
- Reuters. FDA Advisers Recommend Relaxing U.S. Rules on Compounding Peptides.